Instability of Immunophenotype in Plasma Cell Myeloma
نویسندگان
چکیده
منابع مشابه
cutaneous involvement in plasma cell myeloma: report of a case
abstract: plasma cellmyeloma constitutes about 10% of all hematologicmalignancies. metastatic cutaneous lesions without underlying bony involvement are rare and associated with advanced disease, poor prognosis and high tumor burden. igg is the most common subtype and igd is believed to have a more aggressive course.######
متن کاملPlasma cell myeloma
Myeloma is the most common neoplasm of bone.The majority is diagnosed with a bone marrow aspirate, rather than a bone biopsy. Most patients have disseminated disease, associated with a poor prognosis. Some have solitary myeloma with a more favourable clinical course but eventually, most become multifocal. A small percentage of patients have sclerotic bone lesions, which may be associated with p...
متن کاملOrbital plasma cell myeloma.
Orbital plasma cell myeloma is a rare condition. In a review of 222 intraorbital tumours, Forrest (1949) found only one case, and Offret (I951) reported two cases in a series of 676 orbital tumours. Clarke (I 953) emphasized the differentiation between the plasma cell myeloma of myelomatosis and the benign plasma cell tumour produced by chronic inflammation. The present report concerns a case p...
متن کاملPlasma Cell Neoplasms, Clinicopathological Characteristics and Immunophenotype of 21 Patients
Introduction: Plasma cell neoplasms are monoclonal proliferations characterized by the secretion of an immunoglobulin product known as component “M” or monoclonal. The World Health Organization (WHO 2008) defines as plasma cell neoplasms the following: plasma cell myeloma, plasmacytoma and those syndromes defined by immunoglobulin deposits and primary amyloidosis, The objective of the present w...
متن کاملImmunophenotype of Normal and Myelomatous Plasma-Cell Subsets
Plasma cells (PCs) are essentially characterized by the co-expression of CD138 and CD38, which allows their identification in flow cytometry in bone marrow (BM), peripheral blood, or cell suspensions from tissues. These terminally differentiated B-cells may lose the expression of surface CD19 and that of CD20 while retaining CD27. When malignant, they can gain a number of other markers such as ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Clinical Pathology
سال: 2008
ISSN: 0002-9173,1943-7722
DOI: 10.1309/8uvf7yq1d4d4etqv